Literature DB >> 32226619

Position 1: Transarterial Chemoembolization Should Be the Primary Locoregional Therapy for Unrespectable Hepatocelluar Carcinoma.

Wasseem Skef1, Mitali Agarwal2, Adam E Mikolajczyk2.   

Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-reading-skef a video presentation of this article http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-interview-mikolajczyk an interview with the author.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32226619      PMCID： PMC7098666          DOI： 10.1002/cld.909

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  10 in total

1.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

Review 2.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

3.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

Review 4.  Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.

Authors:  Fasiha Kanwal; Amit G Singal
Journal:  Gastroenterology       Date:  2019-04-12       Impact factor: 22.682

5.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

6.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski
Journal:  Gastroenterology       Date:  2016-08-27       Impact factor: 22.682

Review 7.  Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2016-04-28       Impact factor: 6.047

Review 8.  Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.

Authors:  Riccardo Lencioni; Thierry de Baere; Michael C Soulen; William S Rilling; Jean-Francois H Geschwind
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

9.  Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials.

Authors:  Andrea Casadei Gardini; Emiliano Tamburini; Mercedes Iñarrairaegui; Giovanni Luca Frassineti; Bruno Sangro
Journal:  Onco Targets Ther       Date:  2018-10-25       Impact factor: 4.147

Review 10.  Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.

Authors:  Joseph Ralph Kallini; Ahmed Gabr; Riad Salem; Robert J Lewandowski
Journal:  Adv Ther       Date:  2016-04-02       Impact factor: 3.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.